Faruqi & Faruqi, LLP, a leading national securities firm headquartered
in New York City, is investigating the Board of Directors of Comverge,
Inc. (“Comverge” or the “Company”) (NASDAQ: COMV) for potential breaches
of fiduciary duties in connection with their conduct related to the sale
of the Company to the private equity firm H.I.G. Capital in a
transaction valued at about $49 million. Under the terms of the proposed
transaction, Comverge shareholders will receive only $1.75 in cash for
each share of Comverge common stock they own, while according to Yahoo!
Finance, at least one financial analyst has set a price target of $8.65
for Comverge.
Request more information now by clicking here: www.faruqilaw.com/COMV.
There is no cost or obligation to you.
Whether Comverge’s Board of Directors breached their fiduciary duties to
the Company’s stockholders by failing to conduct an adequate and fair
sales process prior to agreeing to this proposed transaction, whether
the proposed transaction undervalues Comverge’s shares and by how much
this proposed transaction undervalues the Company to the detriment of
Comeverge’s shareholders are the key focus of this investigation.
Faruqi & Faruqi, LLP is a national law firm which represents investors
and individuals in class action litigation. The firm is focused on
providing exemplary legal services in complex litigation in the areas of
securities, shareholder, antitrust and consumer litigation, throughout
all phases of litigation. The firm has an experienced trial team which
has achieved significant victories on behalf of the firm’s clients.
If you own common stock in Comverge and wish to obtain additional
information and protect your investment free of charge, please visit us
at www.faruqilaw.com/COMV
or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com
or by telephone at (877) 247-4292 or (212) 983-9330.
Attorney Advertising. (C) 2012 Faruqi & Faruqi, LLP. The law firm
responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).
Prior results do not guarantee or predict a similar outcome with respect
to any future matter. We are happy to discuss your particular case.
